Sagimet Biosciences (SGMT) Stock Price, Quote, News & History

Comments

Sagimet Biosciences Inc (SGMT) Stock Price, Quote, News & History

SGMTNASDAQ

Trade with Public

$5.34

-0.40-6.97%

At close: Mar 12, 5:00 PM EST

$5.63

0.295.43%

After Hours: 9:30 AM EST

Earnings: Q4 2025 Earnings were released on Wed Mar 11th, before the market open

OverviewNews Earnings Options Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$5.62

Close

$5.34

Volume / Avg.

266.12K / 614.89K

Day Range

$5.29 - $5.66

52 Wk Range

1.73 - 11.41

Market Cap

$183.10M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

44

Short Interest

12.74%

Days to Cover

9.32

Recent Sagimet Biosciences Inc News

This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Avi Kapoor

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday

Avi Kapoor

Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps

Denifanstat showed positive Phase 3 results in acne, meeting all goals with strong safety, as Sagimet pushes ahead with a second FASN inhibitor trial.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-44.84M

Investing Cash Flow (TTM)

48.00K

Financing Cash Flow (TTM)

275.00K

Free Cash Flow (TTM)

-44.84M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-44.52M

Analyst Trends and Forecast

2

Oct 25

0

Nov 25

1

Jan

2

Feb

1

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$70.10M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

1.57

Earnings Yield % (TTM)

-31.01%

Earnings Yield % (FWD)

-33.45%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$3.67

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$32.50M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$5.62

Close

$5.34

Volume / Avg.

266.12K / 614.89K

Day Range

$5.29 - $5.66

52 Wk Range

1.73 - 11.41

Market Cap

$183.10M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

44

Short Interest

12.74%

Days to Cover

9.32

About

Sector

Health Care

Industry

Biotechnology

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolis...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Sagimet Biosciences (SGMT) stock?

A

You can purchase shares of Sagimet Biosciences (NASDAQ:SGMT) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Sagimet Biosciences (SGMT) competitors?

A

Other companies in Sagimet Biosciences’s space includes: Macrogenics Inc (NASDAQ:MGNX), Molecular Partners AG (NASDAQ:MOLN), Kalaris Therapeutics Inc (NASDAQ:KLRS), Galectin Therapeutics Inc (NASDAQ:GALT) and Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL).

Q

What is the forecast, or price target, for Sagimet Biosciences (SGMT) stock?

A

Sagimet Biosciences has a consensus price target of $27.73.

Q

What is the current price for Sagimet Biosciences (SGMT)?

A

The stock price for Sagimet Biosciences (NASDAQ: SGMT) is $5.63 last updated March 12, 2026 at 9:30 AM EDT.

Q

Does Sagimet Biosciences (SGMT) pay a dividend?

A

There are no upcoming dividends for Sagimet Biosciences.

Q

When is Sagimet Biosciences (NASDAQ:SGMT) reporting earnings?

A

Sagimet Biosciences does not have any upcoming earnings scheduled.

Q

Is Sagimet Biosciences (SGMT) going to split?

A

There is no upcoming split for Sagimet Biosciences.

Q

What sector and industry does Sagimet Biosciences (SGMT) operate in?

A

Sagimet Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Molecular Partners AG

NASDAQ:MOLN

$5.15

8.54%

Kalaris Therapeutics Inc

NASDAQ:KLRS

$9.17

%

Galectin Therapeutics Inc

NASDAQ:GALT

$3.20

1.25%

Zentalis Pharmaceuticals Inc

NASDAQ:ZNTL

$2.70

-1.85%

ProQR Therapeutics NV

NASDAQ:PRQR

$1.76

2.27%

Connect Biopharma Holdings Ltd

NASDAQ:CNTB

$3.09

9.39%

Elicio Therapeutics Inc

NASDAQ:ELTX

$10.69

-1.96%

Key Statistics

Open

$5.62

Close

$5.34

Volume / Avg.

266.12K / 614.89K

Day Range

$5.29 - $5.66

52 Wk Range

1.73 - 11.41

Market Cap

$183.10M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

44

Short Interest

12.74%

Days to Cover

9.32

Recent Sagimet Biosciences Inc News

This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Avi Kapoor

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday

Avi Kapoor

Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps

Denifanstat showed positive Phase 3 results in acne, meeting all goals with strong safety, as Sagimet pushes ahead with a second FASN inhibitor trial.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-44.84M

Investing Cash Flow (TTM)

48.00K

Financing Cash Flow (TTM)

275.00K

Free Cash Flow (TTM)

-44.84M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-44.52M

Analyst Trends and Forecast

2

Oct 25

0

Nov 25

1

Jan

2

Feb

1

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$70.10M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

1.57

Earnings Yield % (TTM)

-31.01%

Earnings Yield % (FWD)

-33.45%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$3.67

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$32.50M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$5.62

Close

$5.34

Volume / Avg.

266.12K / 614.89K

Day Range

$5.29 - $5.66

52 Wk Range

1.73 - 11.41

Market Cap

$183.10M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

44

Short Interest

12.74%

Days to Cover

9.32

About

Sector

Health Care

Industry

Biotechnology

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolis...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry